Drug intelligence / Profile preview

PER312

Development stage: Preclinical
Lead developer: Perseo Pharma
Modality: Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
Administration: Oral

Overview

**PER312** is a Perseo oral enzyme replacement therapy candidate for congenital sucrase-isomaltase deficiency. It is designed to replace deficient sucrase-isomaltase activity in the small intestine using therapeutic enzymes protected by Perseo's nanotechnology platform, supporting enzyme activity during gastrointestinal transit and enabling digestion of sucrose and starch-derived substrates.

Targets

Sucrase-Isomaltase

Beyond the preview

Go deeper on PER312.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PER312.

Explore the full profile